9,320 reports of this reaction
6.6% of all DROSPIRENONE AND ETHINYL ESTRADIOL reports
#3 most reported adverse reaction
PULMONARY EMBOLISM is the #3 most commonly reported adverse reaction for DROSPIRENONE AND ETHINYL ESTRADIOL, manufactured by Bayer HealthCare Pharmaceuticals Inc.. There are 9,320 FDA adverse event reports linking DROSPIRENONE AND ETHINYL ESTRADIOL to PULMONARY EMBOLISM. This represents approximately 6.6% of all 140,358 adverse event reports for this drug.
Patients taking DROSPIRENONE AND ETHINYL ESTRADIOL who experience pulmonary embolism should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PULMONARY EMBOLISM is moderately reported among DROSPIRENONE AND ETHINYL ESTRADIOL users, representing a notable but not dominant share of adverse events.
In addition to pulmonary embolism, the following adverse reactions have been reported for DROSPIRENONE AND ETHINYL ESTRADIOL:
The following drugs have also been linked to pulmonary embolism in FDA adverse event reports:
PULMONARY EMBOLISM has been reported as an adverse event in 9,320 FDA reports for DROSPIRENONE AND ETHINYL ESTRADIOL. This does not prove causation, but indicates an association observed in post-market surveillance data.
PULMONARY EMBOLISM accounts for approximately 6.6% of all adverse event reports for DROSPIRENONE AND ETHINYL ESTRADIOL, making it one of the most commonly reported side effect.
If you experience pulmonary embolism while taking DROSPIRENONE AND ETHINYL ESTRADIOL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.